With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
FDA Grants Fast Track Designation to MC001 in Pancreatic Cancer
3
NCCN Guidelines Upgrade Cosibelimab to Category 2A for Locally Advanced Cutaneous Squamous Cell Carcinoma
4
PD-L1, Histology, and Safety Profile Guide ICI Selection in NSCLC
5